Candela Receives China Approvals.

WAYLAND, Mass. -- Candela Corporation (NASDAQ: CLZR), a pioneer in the development and commercialization of aesthetic laser systems, announced today that the SFDA (State Food and Drug Administration) of China has approved Candela's GentleYAG(R) and GentleLASE(R) laser systems for sale throughout the People's Republic of China, including Hong Kong.

Candela earlier announced an exclusive distribution agreement with Chindex International, Inc. (NASDAQ: CHDX), a leading independent American provider of western healthcare products and services in the People's Republic of China to market and distribute the extensive Candela product line.

Candela's President and CEO, Gerard E. Puorro, said: "Receiving the approvals to distribute these two superior laser systems in China is an important step to expanding the Chinese market for laser cosmetics and aesthetics."

Candela's Vice President of Asia Pacific Operations, Anthony F.L. Shaw, said: "Chindex and Candela are very pleased to have completed the requirements for registration of both the variable pulse GentleYAG and the GentleLASE products with the SFDA of China. These new approvals will allow Candela to expand its operations in China and provide effective treatments for many more patients. Candela and Chindex are in the process of registering other Candela products for the China market as soon as possible in order to offer the broadest range of treatments to patients."

About Chindex International, Inc.:

Chindex is an American company operating in several healthcare sectors of the Chinese marketplace, including Hong Kong. It provides representative and distribution services to a number of major multinational companies including Siemens AG (ultrasound systems), and Guidant (interventional cardiology products including stents, balloon catheters and guide wires). Its distribution channels to the retail pharmacy industry in China have been developed through a relationship with a major multinational cosmetics manufacturer. It also provides healthcare services through the operations of its private hospital corporation in China. With over twenty-three years of experience, over 700 employees, and operations in the United States, China and Hong Kong, the Company's strategy is to expand its cross-cultural reach by providing leading edge technologies, quality products and services to Greater China's professional communities. Further company information may be found at the Company's websites, www.chindex.com and www.unitedfamilyhospitals.com.

About Candela:

Candela Corporation, an ISO-9001 certified company, develops, manufactures, and distributes innovative clinical solutions that enable physicians, surgeons, and personal care practitioners to treat selected cosmetic and medical conditions using lasers, aesthetic laser systems, and other advanced technologies. Founded near Boston in 1970, the company markets and services its products in over 64 countries from offices and distributors in the United States, Europe, Japan, China and other Asian locations. Candela established the aesthetic laser market 16 years ago, and currently has an installed base of 8,000 lasers worldwide. Candela is an Equal Opportunity and Affirmative Action Employer (Male/Female/Handicapped/Veteran). Visit Candela on the Web at http://www.candelalaser.com.

Safe Harbor Statement: Except for the historical information contained herein, this news release contains forward-looking statements that constitute Candela's current intentions, hopes, beliefs, expectations or predictions of the future, which are therefore inherently subject to risks and uncertainties. Such statements may relate to, among other things, our future revenue, gross margin, expense levels and earnings, our growth prospects, market acceptance of our products, the strength of our distribution channels, our ability to add new products, our ability to expand regulatory approvals and the liquidity of our common stock. The risks and uncertainties that may affect forward-looking statements include, among others: the cancellation or deferral of customer orders, dependence on a small number of strategic distribution relationships, difficulties in the timely development and market acceptance of new products, unanticipated increases in expenses, market developments that vary from the current public expectations concerning the growth of the laser industry, increased competitive pressures, changes in economic conditions, or difficulties in obtaining timely regulatory approvals. Further information on factors that could affect Candela's performance is included in Candela's periodic reports filed with the SEC, including but not limited to, Candela's Annual Report on Form 10-K for the year ended July 2, 2005. Candela cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Candela expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Candela's expectations or any change in events, conditions or circumstances on which any such statement is based.